Related Experiment Video
Updated: Aug 13, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Burden of cardiovascular disease in Canada
Douglas G Manuel1, Mark Leung, Kathy Nguyen
1Institute for Clinical Evaluative Sciences, University of Toronto, Toronto, Ontario, Canada. doug.manuel@ices.on.ca
Insights
Cardiovascular disease (CVD) mortality has decreased in Canada, but it still significantly impacts quality of life and health expectancy. Reducing CVD is crucial for improving population health and reducing health inequalities.
Area of Science:
- Public Health
- Epidemiology
- Health Economics
Background:
- Cardiovascular disease (CVD) remains a leading cause of mortality in Canada.
- Estimates of CVD mortality and disease burden require regular updates.
- Understanding the population-level impact of CVD on quality of life is essential.
Purpose of the Study:
- To update cardiovascular disease (CVD) death estimates in Canada.
- To assess the prevalence of heart disease and its impact on health-related quality of life (HRQOL).
- To analyze the burden of CVD across different demographics and regions.
Main Methods:
- Utilized the Canadian Mortality Database for mortality estimates (1950-1999).
- Employed the Canadian Community Health Survey (CCHS) for prevalence and HRQOL data (2000-2001).
- Applied life table techniques to determine impacts on life and health expectancy.
Main Results:
- CVD death rates declined significantly from 1950-1999 for both men and women.
- Heart disease prevalence was reported by 5.4% of men and 4.6% of women.
- CVD resulted in an estimated loss of 4.5 years of life expectancy and 2.8 years of health expectancy.
- Significant disparities in CVD burden were observed between sexes and across Canadian health regions.
Conclusions:
- CVD imposes a substantial burden on mortality and HRQOL, contributing to health inequalities.
- Interventions targeting CVD reduction are vital for enhancing Canadian health and equity.
- Reducing CVD could lead to greater gains in life expectancy than in health expectancy.
Background:
This report updates the death estimates for cardiovascular disease (CVD) in Canada and introduces a population-based perspective on disease prevalence and health-related quality of life (HRQOL) burden.
Methods:
The Canadian Mortality Database was used to estimate the mortality of men and women in different age groups for the 139 Canadian health regions from 1950 to 1999. Heart disease prevalence and its impact on HRQOL were estimated using the 2000-2001 Canadian Community Health Survey (CCHS). Life table techniques were used to estimate the impact of heart disease on life and health expectancy.
Results:
Although CVD remains the leading cause of death in Canada, between 1950 and 1999 the death rates from CVD dropped from 702 per 100,000 to 288 per 100,000 men, and from 562 per 100,000 to 175 per 100,000 women. Results from the CCHS indicated that 5.4% of men and 4.6% of women reported having heart disease as diagnosed by a medical professional. Of these individuals, 14% of men and 21% of women reported difficulty ambulating - about six times more than people without heart disease. In total, 4.5 years of life expectancy and 2.8 years of health expectancy were lost due to CVD. The study also found large differences in the burden of CVD among men and women and across the 139 Canadian health regions.
Conclusions:
CVD is a major disease burden in terms of both mortality and HRQOL and is an important source of health inequalities between populations in Canada. Any attempt to improve the health of Canadians or to reduce health inequalities should include interventions to reduce CVD mortality and morbidity. Given the present impact of CVD on HRQOL, reducing or eliminating heart disease may potentially result in an increase in life expectancy that will be larger than the gains in health expectancy.
More Related Videos
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Related Concept Videos
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures